UPenn, Penn Medicine and OUP all contributed to an oversubscribed series A round for UPenn spinout Interius Biotherapeutics.
Interius Biotherapeutics, a US-based gene therapy spinout of University of Pennsylvania (UPenn), pocketed $76m in a series A round backed by the institution today.
Penn Medicine, the academic medical centre of UPenn, took part in the round, as did spinout-focused investment firm Osage University Partners.
Cormorant Asset Management and Fairmount Funds co-led the round, which additionally attracted pharmaceutical firm Pfizer’s corporate venture capital arm Pfizer Ventures, Bain Capital Life Sciences, RA Capital Management, Longwood Fund, Logos Capital and…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
